Three Seasons Wealth’s Summit Therapeutics SMMT Stock Holding History

Three Seasons Wealth’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$188K	Hold	12,869	–	–	0.02%	176
2026 Q1	$244K	Hold	12,869	–	–	0.09%	167
2025 Q4	$225K	Hold	12,869	–	–	0.02%	173
2025 Q3	$266K	Hold	12,869	–	–	0.03%	152
2025 Q2	$274K	Hold	12,869	–	–	0.03%	94
2025 Q1	$248K	Hold	12,869	–	–	0.12%	95
2024 Q4	$230K	Hold	12,869	–	–	0.11%	117
2024 Q3	$282K	Hold	12,869	–	–	0.15%	93
2024 Q2	$100K	Hold	12,869	–	–	0.06%	86
2024 Q1	$49.5K	Hold	12,869	–	–	0.03%	79
2023 Q4	$33.6K	Hold	12,869	–	–	0.03%	82
2023 Q3	$24.1K	Buy	+12,869	New	+$24.5K	0.02%	55

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Three Seasons Wealth's SMMT Position: Q2 2026 in Review

Three Seasons Wealth held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 12,869 shares worth $188K. The position accounts for 0.02% of the portfolio, ranked #176.

Three Seasons Wealth first reported a position in SMMT in Q3 2023 and has held it in 12 quarters since. The position peaked at $282K in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Three Seasons Wealth held 12,869 shares of Summit Therapeutics worth $188K as of Q2 2026.
Three Seasons Wealth left its Summit Therapeutics share count unchanged in Q2 2026.
Summit Therapeutics made up 0.02% of Three Seasons Wealth's portfolio in Q2 2026, its #176 holding.
Three Seasons Wealth first reported a position in Summit Therapeutics in Q3 2023 and has held it in 12 quarters since.
Three Seasons Wealth's Summit Therapeutics position peaked at $282K in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Three Seasons Wealth's 13F filing for Q2 2026, filed 13 Aug 2026.